CIPH Ciphergen Biosystems (MM)

Ciphergen Highlights Biomarker Discovery, Identification and Assay Capability at ASMS 21 Scientific Papers and Presentations to be Presented FREMONT, Calif., May 24 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today at the 52nd American Society of Mass Spectrometry (ASMS) conference in Nashville, Tennessee, that leading researchers are presenting biomarker discovery and identification progress across a wide variety of diseases enabled by the use of SELDI ProteinChip(R) technology. The majority of the papers at ASMS emphasize scientific progress being made by Ciphergen's customers in such fields as endometriosis, gastric and lung cancers, diabetes, neurology, pharmaceutical development including drug toxicity and responder/non-responder patient stratification, infectious disease, environmental toxicology and fermentation processes. Several of the papers being presented describe Ciphergen's novel SELDI based proteomics methodologies and improvements including discovery and identification of interacting proteins of Grb2 growth factor receptor using Ciphergen's new Interaction Discovery Mapping(TM) platform; proteomic profiling methodologies using SELDI combined with pattern recognition analysis for multi-biomarker discovery in serum and tissues; and improvements in protein ID and quantitation. "Our focus at ASMS is on the successful use of Ciphergen technology by our customers," stated William E. Rich, President and CEO of Ciphergen. "Ciphergen has pioneered protein biomarker discovery and multi-biomarker assays using SELDI ProteinChip and Biomarker Patterns(TM) products and Biomarker Discovery Center(R) services. Now that proteomics is increasingly being defined as biomarker-driven, our customers are reaping the benefits of our extensive experience in this field. The broad range of real biological problems being solved by biologists at their benchtop using our technologies, products and services is very gratifying." About Ciphergen Ciphergen's Biosystems Division develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, and process proteomics applications, as well as a broad range of bioseparations media for protein purification and large scale production. ProteinChip Systems enable protein discovery, characterization, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Ciphergen's Diagnostics Division is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the use of ProteinChip technology to discover useful protein biomarkers that can act as novel drug targets or disease markers, develop and commercialize clinical diagnostics that improve patient care, the ability to provide services that lead to improved toxicology assays and diagnostic assays, and statements regarding our Diagnostics Division. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology's ability to validate and/or develop protein biomarkers as novel drug targets, diagnostic or toxicology assays, and the Company's ability to successfully commercialize such tests. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K dated March 15, 2004, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip, Biomarker Discovery Center and BioSepra are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers of Ciphergen Biosystems, Inc. Investor Relations, +1-510-505-2233 Web site: http://www.ciphergen.com/

Copyright